Psilocybin, MDMA, Ketamine: The Clinical Evidence for Psychedelics in Mental Health

The Backdrop: Why Psychedelics Are Being Studied Now

For decades, psychedelics were off-limits for research. Scheduling restrictions, political baggage, and lack of funding made clinical investigation nearly impossible. But that changed in the 2010s. Depression treatment plateaued. PTSD remained difficult to treat. Ketamine showed rapid anti-depressant effects in early studies. And researchers started asking: could these compounds actually help people?

We're now in phase 2b and phase 3 trials, the expensive, rigorous studies that precede drug approval. The data is preliminary but increasingly substantial. This is what the evidence actually shows.

Psilocybin for Treatment-Resistant Depression: Johns Hopkins and COMPASS Pathways

Johns Hopkins has emerged as the leading research centre for psilocybin. In 2020, they published results from a small but rigorous trial in JAMA Psychiatry: 24 participants with major depression received two doses of psilocybin (20-30 mg) spaced two weeks apart, combined with intensive psychological support. At two months, 71% showed significant improvement. 54% met criteria for complete remission.

These are extraordinary numbers compared to standard antidepressants, which achieve remission in roughly 30-40% of people. But the sample was small, uncontrolled (no placebo arm), and heavily selected for treatment-seeking motivated people.

COMPASS Pathways ran a larger, phase 2b randomised controlled trial (the gold standard) in 2024. They tested their proprietary psilocybin preparation (COMP360) at 25 mg in 233 people with treatment-resistant depression (TRD—depression that hasn't responded to at least two antidepressants). Results were positive but more modest than Johns Hopkins: 29% of the psilocybin group showed significant response compared to 13% in placebo. The difference was statistically significant but not transformative.

The discrepancy between Johns Hopkins and COMPASS highlights a critical issue: setting and therapeutic support matter enormously. Johns Hopkins involved high-touch, hours-long psychological support. COMPASS was more clinical. The effect of psilocybin is real, but it's not magic without proper context.

MDMA for PTSD: MAPS Phase 3 Results and FDA Drama

The Multidisciplinary Association for Psychedelic Studies (MAPS) has been running MDMA-assisted psychotherapy trials for PTSD since the 2010s. Their most recent phase 3 trial (published in Nature Medicine, 2023) involved 71 people with severe PTSD. Half received MDMA (125 mg) with 12 sessions of psychotherapy. Half received placebo with psychotherapy.

The results were striking: 71% of the MDMA group no longer met criteria for PTSD at 18 weeks. Only 32% of the placebo group did. The effect size (Cohen's d) was 1.44, which is enormous in psychiatric research. MDMA appeared to genuinely accelerate trauma processing and reduce fear conditioning.

The mechanism involves reduced amygdala (fear centre) reactivity while maintaining cortical (thinking) engagement. MDMA helps people process trauma while staying psychologically present and engaged with the experience. It's not about getting high; it's about being in a neurochemical state where trauma reprocessing becomes possible.

However, in late 2024, the FDA rejected MDMA-assisted therapy for PTSD despite the strong clinical data. The reason: elevated blood pressure during sessions. MDMA increases heart rate and blood pressure. In a controlled clinical setting with psychiatric support, this was managed. But the FDA raised safety concerns about broader use, particularly in people with pre-existing cardiovascular conditions.

This is politically contentious. The evidence for MDMA is strong. But safety concerns about cardiovascular effects in certain populations are legitimate. The treatment may still become available, but the pathway is complicated.

Ketamine for Acute Depression: The Only FDA-Approved Psychedelic-Adjacent Treatment

Ketamine is technically a dissociative, not a classic psychedelic, but it's become the closest thing to approved psychedelic treatment for mental health. Spravato (esketamine, the active enantiomer of ketamine) received FDA approval in 2019 for treatment-resistant depression.

The clinical trial showed that intranasal esketamine (56-84 mg) plus oral antidepressant worked better than antidepressant plus placebo in people with TRD. Response rates were roughly 50-65% in responder groups, with effects emerging within 24-72 hours (far faster than traditional antidepressants, which take weeks).

The advantage of ketamine is rapid action. For someone in acute suicidal crisis, the ability to produce improvement in days rather than weeks is life-saving. The disadvantage is that effects are often transient. Many people relapse when ketamine is stopped. It's a bridge, not a cure, unless combined with longer-term treatment.

Ketamine also carries risks: dissociation, abuse potential (intranasal ketamine has higher abuse risk than IV), and long-term use concerns (occupational ketamine exposure is associated with bladder dysfunction and cognitive impairment). When used short-term under medical supervision, it's generally safe. Long-term recreational use is dangerous.

The Mechanism: Default Mode Network and Neuroplasticity

What connects psilocybin, MDMA, and ketamine despite their different pharmacology? They all disrupt the default mode network (DMN), the brain's self-referential thinking system. In depression and PTSD, the DMN is overactive and inflexible. People get stuck in patterns of self-blame, future catastrophizing, and fear conditioning.

Psychedelics quieten the DMN. They temporarily disrupt the fixed patterns of thought. They increase neuroplasticity (formation of new neural connections). And if this disruption is paired with psychological work (therapy, integration, processing), new patterns can be established.

This is why set and setting matter. A psychedelic in isolation is just a perceptual and emotional experience. A psychedelic paired with structured psychological support becomes a therapeutic tool for reconfiguring thought patterns and emotional responses.

Microdosing: The Weakest Evidence

Microdosing—taking sub-perceptual doses of psilocybin or LSD (typically 10% of a recreational dose) regularly to improve mood, creativity, or cognition—is extremely popular but has the weakest evidence.

Most microdosing studies have been small, self-selected, and plagued by lack of blinding (people can usually tell if they're microdosing versus placebo, even at low doses). A 2022 randomised, placebo-controlled trial published in Nature Human Behaviour tested microdosing psilocybin in 190 people. They found no significant difference between microdosing and placebo on mood, cognition, or wellbeing.

This doesn't mean microdosing does nothing—some people report genuine benefit—but the evidence for a reliable therapeutic effect is weak. If people improve, it might be partly placebo, partly expectation effect, and partly the dopamine/serotonin boost from believing they're doing something positive.

Safety Profile: What Actually Matters

Psilocybin and LSD are physiologically very safe. You can't overdose lethally. They don't damage organs. Addiction potential is essentially zero (they don't trigger dopamine reward pathways in the way addictive drugs do).

The risks are psychological: triggering latent psychosis in genetically susceptible people, challenging emotional experiences during acute effects, and longer-term dissociation or depersonalization in vulnerable individuals. Risk screening (psychiatric history, family history of psychosis) is essential.

MDMA carries more physiological risk: elevated blood pressure and heart rate, potential serotonin syndrome if combined with other serotonergic drugs, and pre-existing cardiovascular vulnerability matters. Ketamine risks include dissociation, acute blood pressure elevation, and long-term safety with repeated use unknown beyond controlled settings.

All three require proper medical supervision in clinical settings. Self-administration or "underground therapy" lacks the safety infrastructure and psychiatric support that clinical trials provide.

UK Legal Status and Access

In the UK, psilocybin is a Schedule I drug under the Misuse of Drugs Act. Possession is illegal. Clinical research is possible with Home Office licensing, but no trials are currently active in UK clinical settings. Psilocybin-assisted therapy is not available on the NHS.

MDMA is similarly Schedule I. Ketamine/esketamine is Schedule III, meaning it's available on prescription (as Spravato) but only in specialized psychiatric settings.

Access in the UK currently requires either private clinics (which offer ketamine IV therapy, increasingly common in London and other cities), clinical trial participation (rare), or travelling to legal jurisdictions (Canada, some US states have legal or decriminalised psilocybin clinics).

What to Expect: Timeline and Realistic Outcomes

If psilocybin or MDMA-assisted therapy become available legally in the UK (likely 5-10 years for psilocybin, unclear for MDMA), expect: a full-day session (6-8 hours), intensive psychological preparation, medical monitoring, integration therapy afterward, and costs of 5,000-15,000 pounds per therapeutic course.

Response rates are approximately: psilocybin 50-70% significant improvement (varies by trial), MDMA 70% symptom reduction in PTSD, ketamine 50-60% acute response. But "significant improvement" often means reduction in symptoms, not complete remission. Most people still need ongoing support.

The Bottom Line: Promise and Limitations

Psychedelics show genuine clinical promise for depression and PTSD that's resistant to conventional treatment. The evidence base is growing, the effect sizes are large, and the safety profile (with proper screening) is reasonable.

But they're not magic. They're tools that work best in specific conditions: treatment-resistant cases, high motivation for psychological work, proper psychiatric support, and appropriate screening for contraindications. They're faster than traditional antidepressants but not risk-free. And long-term outcomes remain unclear.

The excitement is warranted, but expectations need to be realistic. These are valuable therapies for specific populations, not panaceas, and certainly not recreational toys.